{"id":873,"date":"2001-10-15T00:00:00","date_gmt":"2001-10-15T00:00:00","guid":{"rendered":""},"modified":"-0001-11-30T00:00:00","modified_gmt":"-0001-11-30T04:00:00","slug":"local-biotech-industry-hurt-by-geneprot-move","status":"publish","type":"post","link":"https:\/\/hedgeco.net\/news\/10\/2001\/local-biotech-industry-hurt-by-geneprot-move.html","title":{"rendered":"Local biotech industry hurt by GeneProt move"},"content":{"rendered":"<p>In a major set-back for Chicago&#8217;s biotech industry, two major upstarts left Illinois over the last several weeks. Evanston-based GeneProt decided to pull up stakes and relocate operations to NewJersey late last month.<\/p>\n<p>  GeneProt is a leading proteomics company, and according to Michael Becker, a co-founder of the Chicago Biotech Network, &#8220;It&#8217;s a huge loss.<\/p>\n<p>  They are at the forefront of the industry.&#8221; Proteomics involves the systematic study of proteins, and has broad applications in the development of new drug therapies and diagnostics.<\/p>\n<p>  NephRX, a local biotech company that developed a treatment for kidney disease, was wooed away earlier this month to the Innovation Center in Kalamazoo, Mich. Its founding scientist, F. Gary Toback,  is a University of Chicago nephrologist, and the company was one of the first companies spun out by the former ARCH Development Corp. (ADC) at the university.<\/p>\n<p>  &#8220;We were investors in the company from Day 1,&#8221; noted Tom Churchwell, former head of ADC who left his post this summer to launch a new fund called ARCH Development Partners.<\/p>\n<p>  Churchwell&#8217;s fund received $6.5 million from Kalamazoo investors and from Southwest Michigan First. The fund in turn made one of its first investments in NephRX last month.<\/p>\n<p>  &#8220;Companies go where the CEO and the money are, not necessarily where the technology was developed,&#8221; he explained about the company&#8217;s move out of state. The problem is that New Jersey especially,  and to a lesser degree, Michigan have well-defined goals, initiatives and crucial funding to create centers of biotech &#8211; &#8211; and Chicago does not.<\/p>\n<p>  GeneProt CEO Cedric Loiret-Bernal, M.D., stated: &#8220;The state of New Jersey has awarded GeneProt numerous incentives, including a generous construction allowance in excess of $6 million.<\/p>\n<p>  This greatly supports our speed-to-market strategy, and allows us to apply resources elsewhere, for example, in recruitment and R&amp;D.&#8221;<\/p>\n<p>  The New Jersey Economic Development Authority earlier this year awarded GeneProt a Business Employment Incentive Program grant worth an estimated $3.3 million over 10 years to encourage the  company&#8217;s move to New Jersey.<\/p>\n<p>  Female VC sets up shop here Lisa Kaufman is part of a growing minority making an impact on the high-tech landscape in Chicago: female venture investor.<\/p>\n<p>  After selling off the assets to an integrated voice and data telecom she co-founded in D.C., Kaufman founded Broadgate Ventures in Chicago last July.<\/p>\n<p>  Kaufman already made her first investment into Chicago-based Network Ninja, a Web-based applications firm founded by Matt Bochneak that has customers and revenues.<\/p>\n<p>  Kaufman declined to note the investment amount because the round of funding is still open&#8211;meaning they are looking to attract other investors before the round is closed.<\/p>\n<p>  Bochneak and his executive team met Kaufman during the summer and closed on the investment about a month later.<\/p>\n<p>  &#8220;She has been a great help to our company.<\/p>\n<p>  She has a lot of contacts around the city.<\/p>\n<p>  I think Broadgate will be a very successful firm.&#8221;<\/p>\n<p>  &#8220;I love working with companies in their formative stages,&#8221; said Kaufman.<\/p>\n<p>  She said the investment amount will vary between $100,000 and $1 million per deal. &#8220;I am looking to fund 10 companies over the next two years&#8221; she said, and she also wants most of her investment to  go into Chicago early-stage firms.<\/p>\n<p>  Springboard aims to polish local women entrepreneurs<\/p>\n<p>  Springboard, an organization designed to bring women entrepreneurs together with venture capital, held its first venture forum in the Midwest in May.<\/p>\n<p>  Of the 26 presenting companies, nine have already received funding and several more are close to securing investment capital, according to Linda Darragh from the Women&#8217;s Business Development  Center.<\/p>\n<p>  The problem is that only one of the nine firms funded are from Illinois&#8212;the remainder are spread out through the Midwest. &#8220;What we realized is that there is a real need to set up an educational  base to help local women gain venture capital in future Springboard forums,&#8221; said Darragh. In response, Springboard will not be holding a VC conference in 2002 but will instead launch a series of  educational workshops beginning with &#8220;Access to Equity Bootcamp&#8221; on Nov. 1, in partnership with the Women&#8217;s Business Development Center.<\/p>\n<p>  Darcy Evon is editor of the i-Street Reporter, an independent free Internet newsletter and i-Street magazine. She can be reached at istreet@i-street.com.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In a major set-back for Chicago&#8217;s biotech industry, two major upstarts left Illinois over the last several weeks. Evanston-based GeneProt decided to pull up stakes and relocate operations to NewJersey late last month. GeneProt is a leading proteomics company, and [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-873","post","type-post","status-publish","format-standard","hentry","category-hedgeco-news"],"_links":{"self":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/posts\/873","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/comments?post=873"}],"version-history":[{"count":0,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/posts\/873\/revisions"}],"wp:attachment":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/media?parent=873"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/categories?post=873"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/tags?post=873"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}